Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Pfizer’s Lyrica shows no relief from post-traumatic nerve pain

Written by: | no-reply@reuters.com | Dated: Wednesday, November 25th, 2015

Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study.

The drug did not lead to pain reduction in patients compared with a placebo, the company said on Wednesday.

Currently, there is no approved treatment in the United States for post-traumatic neuropathic pain.

Lyrica, which generated $1.22 billion in sales in the third quarter, is already approved to treat nerve pain associated with diabetes, shingles, spinal cord injury and fibromyalgia.

 

(Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)

Source: Reuters Health

http://www.reuters.com/article/2015/11/25/us-pfizer-study-idUSKBN0TE1MN20151125

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom